Scleroderma or systemic sclerosis is a chronic connective tissue disease generally classified as an autoimmune rheumatic diseases. The word “scleroderma” comes from two Greek words: “sclero” meaning hard, and “derma” meaning skin. Hardening of the skin is one of the most visible manifestations of scleroderma.The exact cause or causes of scleroderma are still unknown, but scientists and medical researchers are working hard to make those determinations.
Meet António Pereira who has lived with and fought against Scleroderma for 40 years.
Meet Tânia Vieira who talks about the biggest passion many mothers can relate to.
Elsa Mateus – President of the Portuguese League Against Reumatic Diseases talks about the importance of patient associations.
Meet Rute from our World Scleroderma Day poster, who have decided that Scleroderma will never overcome her.
FESCA, the Federation of European Scleroderma Associations, is ready to celebrate another World Scleroderma
Day with a campaign to raise awareness of Scleroderma, also known as Systemic Sclerosis.
The Project Scleroderma Patient Support App, among other features, allows patients to track and chart symptoms on a daily basis and keep a running diary of notes to share with their physicians.
Press Release – Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
In April, FESCA and the Scleroderma Society of Canada signed an agreement with Boehringer Ingelheim with the intention of working together to advance clinical research and improve awareness of systemic sclerosis (SSc) also known as scleroderma.
Boehringer-Ingelheim has developed an illustrated infographic (like a cartoon) on systemic sclerosis.
PRESS RELEASE: To celebrate World Scleroderma Day 2015, FESCA held the European Parliamentary event “Unveiling Scleroderma: Hidden Truth” on June 30 in Brussels.
Watch a specially recorded message for World Scleroderma Day 2015 by Ms. Ramona Kanters.
This World Scleroderma Day 2015 we will be “unveiling Scleroderma”.
Encouraging results were seen for tocilizumab (Actemra) in the treatment of diffuse systemic sclerosis (SSc) in a proof-of-concept study by Christopher P. Denton, MBBS, of University College Londo.
With few approved drugs available in SSc, this approach could significantly improve the treatment options in the future.
Often we catch a word related to scleroderma which we do not understand and makes it even more difficult to explain to family and friends.
FESCA, Federation of European Scleroderma Associations aisbl, encourages and undertake surveys, research projects and clinical trials related to the systemic sclerosis disease, and the publication of the results of any such research.
FESCA is always looking for better therapies. This is why we are partners with many different pharma companies. Pay our Scleroderma projects section a visit, and learn more about scleroderma research projects we're involved in.